Ramipril efficacy in slowing CKD progression enhanced in obese subjects. PDF Print
EurekAlert: Ramipril lowered the risk of progression to ESRD in all three weight groups. However, the magnitude of risk reduction was much greater for obese patients: 86 percent, compared to 45 percent in normal-weight patients. Thus, obese patients taking ramipril exhibited about the same ESRD risk as normal-weight patients.

...

 
Share |
Copyright © 2026 Global Dialysis. All Rights Reserved.